Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients

AIDS Reader

Volumn 15, Issue 2, 2005, Pages

  Panther, Lori A ^a   Schlecht, Hans P ^a   Dezube, Bruce J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anal carcinoma; Dysplasia; HIV AIDS; Human papillomavirus; Papanicolaou smear

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CIDOFOVIR; CISPLATIN; FLUOROURACIL; HEAT SHOCK PROTEIN 65; IMIQUIMOD; INTERFERON; MITOMYCIN; PROTEIN E7; VIRUS VACCINE; ZIDOVUDINE;

ANUS CARCINOMA; ANUS DISEASE; ANUS DYSPLASIA; BONE MARROW SUPPRESSION; CANCER INVASION; CLINICAL TRIAL; DIAGNOSTIC TEST; DIARRHEA; DYSPLASIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; INCIDENCE; LYMPHOCYTE COUNT; MALE; NONHUMAN; PAPANICOLAOU TEST; PATHOGENESIS; PRECANCER; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; WART VIRUS; ANUS TUMOR; COMPARATIVE STUDY; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MASS SCREENING; NEEDLE BIOPSY; PAPILLOMA VIRUS; PATHOLOGY; PROGNOSIS; RECTOSCOPY; RISK ASSESSMENT; SURVIVAL; UNITED STATES; VIRUS INFECTION;

ANUS NEOPLASMS; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROCTOSCOPY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

EID: 14544273330     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3-8.
2. Palefsky JM, Holly EA, Gonzales J, et al. Natural history of anal cytologic abnormalities and papillomavirus infection among homosexual men with group IV HIV disease. J Acquir Immune Defic Syndr. 1992;5:1258-1265.
3. Kiviat NB, Critchlow CW, Holmes KK, et al. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS. 1993;7:43-49.
4. Critchlow CW, Surawicz CM, Holmes KK, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS. 1995;9:1255-1262.
5. Palefsky JM, Holly EA, Ralston ML, et al. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med. 1997;73:174-180.
6. Critchlow CW, Hawes SE, Kuypers JM, et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS. 1998;12: 1177-1184.
7. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177:361-367.
8. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31:96-99.
9. Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol. 1994;83:205-211.
10. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001;183:383-391.
11. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138:453-459.
12. zur Hausen H. Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690-698.
13. Palefsky JM, Holly EA, Gonzales J, et al. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res. 1991; 51:1014-1019.
14. Holly EA, Ralston ML, Darragh TM, et al. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst. 2001;93:843-849.
15. Palefcky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr. 1998;17:314-319.
16. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS. 1998;12:495-503.
17. Clarke B, Chetty R. Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. Mol Pathol. 2002;55:19-24.
18. US Department of Health and Human Services. Cases of HIV Infection and AIDS in the United States, 2002. Rockville, Md: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 2002;14:1-48.
19. Louie JK, Hsu LC, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002;186:1023-1027.
20. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317:973-977.
21. Frisch M, Smith E, Grulich A, et al. Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am J Epidemiol. 2003;157:966-972.
22. Goedert JJ, Cote TR, Virgo O, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998; 351:1833.
23. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000; 92:1522-1528.
24. Panther LA, Wagner KT, Doweiko JP, et al. Substantial incidence of histologically proven high-grade anal intraepithelial neoplasia in surgically excised condylomata in HIV-positive and HIV-negative men who have sex with men. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America; September 30-October 3, 2004; Boston. Abstract 888.
25. Trombetta LJ, Place RJ. Giant condyloma acuminatum of theanorectum; trends in epidemiology and management Report of a case and review of the literature. Dis Colon Rectum. 2001;44:1878-1886.
26. Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354-356.
27. Lekhman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med. 1985;78: 211-215.
28. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15:2040-2049.
29. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527-2539.
30. Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44: 127-131.
31. Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44:1496-1502.
32. Place RJ, Gregorcyk SG, Huber PJ, et al. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum. 2001;44:506-512.
33. Palefsky JM, Holly EA, Hogeboom Q, et al. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:415-422.
34. Darragh TM, Jay N, Tupkelewicz BA, et al. Comparison of conventional cytologic smears and Thin-Prep preparations from the anal canal. Acta Cytol. 1997;41:1167-1170.
35. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
36. Nayar R, Solomon D. Second edition of 'The Bethesda System for reporting cervical cytology'-atlas, website, and Bethesda interobserver reproducibility project. Cytojournal. 2004;1:4.
37. Panther LA, Wagner K, Proper J, et al. High resolution anoscopy findings for men who have sex with men: inaccuracy of anal cytology as a predictor of histologic high-grade anal intraepithelial neoplasia and the impact of HIV serostatus. Clin Infect Dis. 2004;38:1490-1492.
38. Panther LA, Wagner KT, Proper J, et al. Use of human papillomavirus (HPV) typing to predict histologically-proven high-grade anal intraepithelial neoplasia (AIN) in HIV+ and HIV- men who have sex with men (MSM) with low-grade abnormalities on anal Pap smear. Presented at the 7th Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research; April 28-29,2003; Bethesda, Md. Abstract 640.
39. Jay N, Berry JM, Hogeboom CJ, et al. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum. 1997;40:319-928.
40. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822-1829.
41. Freedberg KA, Scharfstein JA, Seage GR 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279:130-136.
42. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. MMWR. 2002; 51:RR-8.
43. New York State AIDS Malignancy Consortium. Criteria for the medical care of adults with HIV infection. New York State Department of Health AIDS Institute. March 2004:1-18.
44. Masur H, Kaplan JE, Holmes KK, et al. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137: 435-478.
45. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609-629.
46. Kreuter A, Hochdorfer B, Stucker M, et al. Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J Am Acad Dermatol. 2004;50:980-981.
47. Orlando G, Fasolo MM, Beretta R, et al. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS. 2002;16:447-450.
48. Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma: a prospective randomized trial. Dis Colon Rectum. 1994;37:1255-1259.
49. Chang GJ, Berry JM, Jay N, et al. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum. 2002;45: 453-458.
50. Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr. 2001;28:422-428.
51. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004;37:1563-1565.
52. Kouteky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
53. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase 1 study of ZYC101. Clin Cancer Res. 2002;8:1028-1037.
54. Palefsky JM, Goldstone SE, Neefe J. HspE7 treatment of high-grade anal dysplasia: final results of an open-label trial and interim long-term follow-up. Presented at the 20th International Papillomavirus Conference; October 4-9, 2002; Paris. Abstract H-1600.